Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o. — Clinical Trial Site

110 Registered trials

45 Currently recruiting

Organisation

Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.

Location

Szczecin, Poland

Identifier

ORG-100040198

Address

Ul. Juliusza Slowackiego 19, 71-434, Poland

Departments

-
„Twoja Przychodnia SCM”
#40743: Twoja Przychodnia SCM
#PL10002: Gastrology
40743: Dermatology
5210: Twoja Przychodnia SCM
Dermatologia
Dermatology
Gastroenterology
n.d.
N/A
NA
Not applicable
PL10020:Twoja Przychodnia SCM
PL10022_Twoja Przychodnia SCM
PL10023: Twoja Przychodnia - SCM
Podmiot leczniczy: Twoja Przychodnia
Podmiot leczniczy: Twoja Przychodnia SCM
Site: TWOJA PRZYCHODNIA Szczecińskie Centrum Medyczne/ ul. Juliusza Słowackiego 19, 71-434 Szczecin
TBC
Twoja Przychodnia - SCM
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Twoja Przychodnia – SCM
Twoja Przychodnia – Szczecińskie Centrum Medyczne
Twoja Przychodnia SCM
TWOJA PRZYCHODNIA SCM Poradnia dermatologiczna
Twoja Przychodnia SCM, Poradnia Ginekologiczno-Położnicza
Twoja Przychodnia Szczecinskie Centrum Medyczne
Twoja PrzychodniaSCM

Clinical trials at this site (110)

Search interface

A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis Recruiting

2023-503859-10-00 Moderate to Severe Plaque Psoriasis 5 2024-08-12
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV Recruiting

2023-509046-36-00 Active Ulcerative Colitis (UC) or Crohn's disease (CD) 5 2023-04-26
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn’s Disease (SHINE-ON) Recruiting

2023-506239-14-00 Crohn’s Disease 5 2022-12-13
A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting

2023-509045-13-00 Moderately to severely active Crohn's disease (CD) 5 2022-02-28
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended

2024-519370-40-00 Alopecia areata 5 2025-07-16
A Study to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis Ended

2024-510849-34-00 Eosinophilic Esophagitis 4 2025-02-04
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Severe hypertriglyceridemia (SHTG) 5 2024-11-04
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Hypertriglyceridemia 5 2024-11-04
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A study to evaluate the efficacy and safety of AMY109 in women with endometriosis Ended

2023-507289-14-00 Endometriosis 4 2024-10-21
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05